by Cara Martinez, Cedars-Sinai Medical Center Credit: Pixabay/CC0 Public Domain Experts from Cedars-Sinai Cancer have analyzed patient samples, along with studies conducted in animal models, to identify a novel immune checkpoint pathway to treat hepatocellular carcinoma, the most common form of liver cancer. This big data analysis, coupled with existing immune boosting therapies, provides a...
by Queen Mary, University of London Figure S1A. Principal Component Analysis (PCA) of cell line phosphoproteomic data. PCA demonstrates distribution of data according to cell line (intra-hepatic cholangiocarcinoma (CCA) (HuH-28, KKU-213, HuCCT1, OZ), extra-hepatic CCA (CCC-5, TFK-1, EGI-1), gallbladder cancer (TGBC24TKB, TGBC1TKB), benign biliary (MMNK-1) and benign epithelial (MCF-10A). Credit: DOI: 10.1158/0008-5472.CAN-21-0955 Researchers at King’s College...
by Kathy Keatley Garvey, UC Davis Pancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer Institute A drug candidate discovered and developed decades ago in the laboratory of UC Davis distinguished professor Bruce Hammock may help control the body’s raging and often deadly inflammatory response to chemotherapy treatments, especially for...
by Osaka City University Researchers at the Department of Hepatology of Osaka City University Graduate School of Medicine introduced sorafenib to patients with advanced stages of the liver cancer hepatocellular carcinoma (HCC) and measured the amount of 16 circulating soluble immune checkpoint proteins. Their data suggest that a high amount of sBTLA proteins may be...
